Teladoc expanded continuum of virtual care services enabled, including access to specialty and complex care; streamlined diagnostic test orders

Teladoc Health (NYSE: TDOC), the global leader in virtual care, announces today new capabilities that enable health systems to deliver a broader spectrum of virtual care services and to streamline diagnostic testing orders. The licensed virtual platform and its expanded capabilities will be showcased live during the HIMSS19 Global Conference & Exhibition,February 11-15, in Orlando… READ MORE

double exposure image of virtual human 3dillustration on blue circuit board background represent artificial 
intelligence AI technology

Cardinal Analytx Bounds into Next Growth Phase with Former DecisionView CEO Linda Hand at Helm

Cardinal Analytx Solutions, a developer of advanced machine learning solutions for improving healthcare while reducing costs by predicting impending medical conditions, today announced it has hired healthcare veteran Linda T. Hand as CEO to lead the company through its next phase of growth. Formerly president and CEO of DecisionView, Hand joins Cardinal Analytx at a pivotal time of significant company momentum, with two new advisors also coming aboard….  READ MORE


Vitals Launches MEG – A Medical Expertise Guide for Health Care Shopping

Vitals announced the launch of its new Medical Expertise Guide (MEG) solution to provide consumers the confidence they need when shopping for surgical procedures. MEG combines quality measures, predictive analytics and proprietary confidence measures – along with end-to-end assistance from highly-trained health care professionals – to support consumers throughout their care journey and help them select the highest quality facility and physician for their care….  READ MORE


Abide Therapeutics Announces Initiation of Phase 2 Clinical Trial of ABX-1431 in Tourette Syndrome

Abide Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting the serine hydrolase family of enzymes, announced today the initiation of Phase 2 clinical development of ABX-1431, a first-in-class investigational monoacylglycerol lipase (MGLL) inhibitor, in patients with Tourette Syndrome (TS). TS is a neurodevelopmental disorder characterized by sudden …  READ MORE

Scroll to top